The predictive powers of DFS for breast cancer were compared between the model with clinical variables alone and the model with combined clinical and genetic variables, and the latter tended to have better predictive powers in overall (Harrell’s Cclinical model = 70.92% and Harrell’s Ccombined model = 71.37%, p = 0.03), HR+ HER2- (Harrell’s Cclinical model = 65.08% and Harrell’s Ccombined model = 66.69%, p<0.01), and HR- HER2- breast cancer (Harrell’s Cclinical model = 63.26% and Harrell’s Ccombined model = 65.88%, p<0.01). The gene discussed is ERBB2; the disease is breast carcinoma.